← Back to all trials
Completed
NCT06550128
Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).
Conditions: Hepatitis B, Chronic
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 86
Sponsor: Ausper Biopharma Co., Ltd.
Location: Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou Fujian
Summary
AB-10-8003 is a randomized, multi-center phase II study to evaluate the efficacy and safety of AHB-137 in subjects with HBeAg-negative CHB under stable NA treatment.
Eligibility Criteria
Inclusion Criteria:
1. Participants voluntarily participate in the study, and sign the Informed Consent Form (ICF) prior to screening, able to complete the study and discontinue their NA therapy according to the protocol;
2. At least 18 years old at the time of signing of the informed consent;
3. Body Mass Index (BMI) between 18 to 32 kg/m\^2(inclusive) ;
4. Participants who are Hepatitis B envelop antigen (HBeAg) negative during screening;
5. Participants whose serum HBsAg positive for at least 6 months prior to screening;
6. Participants who have stable on NA therapy at least 6 months prior to screening;
7. Participants with HBsAg concentration \>100 IU/mL and≤3000 IU/mL, HBV DNA\ 9.0 kPa when screening;
6. Diagnosed or suspected hepatocellular carcinoma;
7. The laboratory examination results are obviously abnormal;
8. History of vasculitis or signs and symptoms of potential vasculitis;
9. History of extrahepatic disease that may be related to HBV immune status;
10. Administration of immunosuppressants within 3 months prior to screening, except for short-term use (≤2 weeks) or topical/inhaled steroids. Administration of immunomodulators (thymosin) and cytotoxic drugs within 6 months prior to the first study intervention or have a history of vaccination within 1 month prior to screening or planned administration during the study.
11. Administration of any Interferon within 6 months prior to screening;
12. History of malignant tumor within the past 5 years;
13. Any suspicion of drug component allergy, or allergic constitution (various drug and food allergy, and judged by the investigator to be clinically significant) in participants;
14. Participants who have significant trauma or major surgery within 3 months before screening, or plan to perform surgery during the study;
15. Blood donation or blood loss more than 400 mL within 12 weeks before screening; Blood transfusion; Blood donation or blood loss not less than 200 mL within 1 month before screening;
16. Concurrently participating in another clinical study, or received an investigational product within the following time period prior to the first dosing day in the current study: 5 half-lives or twice the duration of the biological effect of the study treatment or 90 days;
17. Any oligonucleotide or siRNA treatments within 12 months prior to first dosing;
18. Any other circumstances or conditions for which the investigator considers that the participants are inappropriate to participate in the study.
Source: ClinicalTrials.gov (NCT06550128). StuddyBuddy aggregates publicly available trial information.